These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33154299)

  • 1. Circulating free DNA as a marker of response to chemoradiation in locally advanced head and neck squamous cell carcinoma.
    Verma T; Kumari S; Mishra S; Rastogi M; Tiwari V; Agarwal GR; Anand N; Husain N
    Indian J Pathol Microbiol; 2020; 63(4):521-526. PubMed ID: 33154299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saliva-based cell-free DNA and cell-free mitochondrial DNA in head and neck cancers have promising screening and early detection role.
    Sayal L; Hamadah O; Almasri A; Idrees M; Thomson P; Kujan O
    J Oral Pathol Med; 2023 Jan; 52(1):29-36. PubMed ID: 36459078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards effectiveness of cell free DNA based liquid biopsy in head and neck squamous cell carcinoma.
    Kowal-Wisniewska E; Jaskiewicz K; Bartochowska A; Kiwerska K; Ustaszewski A; Gorecki T; Giefing M; Paluszczak J; Wierzbicka M; Jarmuz-Szymczak M
    Sci Rep; 2024 Jan; 14(1):2251. PubMed ID: 38278927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of circulating DNA in malignant neoplasia from diverse locations: Investigating a diagnostic role.
    Kumari S; Mishra S; Husain N; Verma T; Tiwari V; Kaif M; Agarwal A; Rastogi M; Shukla S; Sonkar AA
    Indian J Pathol Microbiol; 2022; 65(1):93-99. PubMed ID: 35074971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy.
    Zwirner K; Hilke FJ; Demidov G; Ossowski S; Gani C; Rieß O; Zips D; Welz S; Schroeder C
    Radiother Oncol; 2018 Dec; 129(3):575-581. PubMed ID: 30097252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating free DNA integrity index and promoter methylation of tumor suppressor gene P16, DAPK and RASSF1A as a biomarker for oropharyngeal squamous cell carcinoma.
    Kumari S; Mishra S; Anand N; Hadi R; Rastogi M; Husain N
    Pathol Res Pract; 2023 Jun; 246():154489. PubMed ID: 37150134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and Therapeutic Applications of Exosomes in Cancer with a Special Focus on Head and Neck Squamous Cell Carcinoma (HNSCC).
    Ebnoether E; Muller L
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32570802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients.
    Mazurek AM; Rutkowski T; Fiszer-Kierzkowska A; Małusecka E; Składowski K
    Oral Oncol; 2016 Mar; 54():36-41. PubMed ID: 26786940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the impact of intra-tumoural heterogeneity on liquid biopsy cell-free DNA methylation and copy number in head and neck squamous cell carcinoma.
    Payne K; Suriyanarayanan H; Brooks J; Mehanna H; Nankivell P; Gendoo D
    Oral Oncol; 2024 Nov; 158():107011. PubMed ID: 39236578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
    Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
    Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma.
    Ahn D; Lee GJ; Sohn JH; Lee JE
    Cancer Med; 2020 Dec; 9(24):9256-9265. PubMed ID: 33073917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
    Tinhofer I; Konschak R; Stromberger C; Raguse JD; Dreyer JH; Jöhrens K; Keilholz U; Budach V
    Ann Oncol; 2014 Oct; 25(10):2042-2047. PubMed ID: 25057171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-free DNA and circulating tumor cell kinetics in a pre-clinical head and neck Cancer model undergoing radiation therapy.
    Muhanna N; Eu D; Chan HHL; Douglas C; Townson JL; Di Grappa MA; Mohamadi RM; Kelley SO; Bratman SV; Irish JC
    BMC Cancer; 2021 Oct; 21(1):1075. PubMed ID: 34600526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
    Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
    Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations.
    Nygård L; Ahlborn LB; Persson GF; Chandrananda D; Langer JW; Fischer BM; Langer SW; Gabrielaite M; Kjær A; Rosenfeld N; Mouliere F; Østrup O; Vogelius IR; Bentzen SM
    PLoS One; 2020; 15(4):e0231884. PubMed ID: 32343749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
    Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
    Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).
    Economopoulou P; Kotsantis I; Kyrodimos E; Lianidou ES; Psyrri A
    Oral Oncol; 2017 Nov; 74():83-89. PubMed ID: 29103757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma.
    De Felice F; Vetrone L; Bulzonetti N; Caiazzo R; Marampon F; Musio D; Tombolini V
    Med Oncol; 2019 Jun; 36(8):68. PubMed ID: 31190132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes.
    Yang WY; Feng LF; Meng X; Chen R; Xu WH; Hou J; Xu T; Zhang L
    Expert Rev Mol Diagn; 2020 Dec; 20(12):1213-1227. PubMed ID: 33232189
    [No Abstract]   [Full Text] [Related]  

  • 20. High expression of MLANA in the plasma of patients with head and neck squamous cell carcinoma as a predictor of tumor progression.
    Rodrigues-Junior DM; Tan SS; Lim SK; de Souza Viana L; Carvalho AL; Vettore AL; Iyer NG
    Head Neck; 2019 May; 41(5):1199-1205. PubMed ID: 30803092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.